These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 121158)

  • 1. Mechanism of central action of octopamine.
    Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1979; 31(5):509-16. PubMed ID: 121158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of central actions of intraventricularly administered octopamine, phenylethylamine and adrenaline in rats.
    Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1983; 35(1):59-62. PubMed ID: 6412221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of octopamine on GABA-ergic transmission in rats.
    Jagiełło-Wójtowicz E; Chodkowska A
    Pol J Pharmacol Pharm; 1984; 36(6):595-601. PubMed ID: 6100132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trace amines inhibit the electrically evoked release of [3H]acetylcholine from slices of rat striatum in the presence of pargyline: similarities between beta-phenylethylamine and amphetamine.
    Baud P; Arbilla S; Cantrill RC; Scatton B; Langer SZ
    J Pharmacol Exp Ther; 1985 Oct; 235(1):220-9. PubMed ID: 3930699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central action of phenylethylamine in rats.
    Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1981; 33(1):59-71. PubMed ID: 7196039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and long-term effects of intraventricular 6-hydroxydopamine in rats pretreated with a monoamine oxidase inhibitor.
    Vetulani J; Reichenberg K; Wiszniowska G; Marchaj J
    Pol J Pharmacol Pharm; 1977; 29(6):645-56. PubMed ID: 564059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central effects of octopamine administered into the lateral ventricle of rats.
    Kleinrok Z; Jagiełło-Wójtowicz E; Szkilnik E
    Acta Physiol Pol; 1979; 30(4):445-53. PubMed ID: 228526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of the central effects of 5,6-dihydroxytryptamine.
    Longo VG; Scotti de Carolis A; Liuzzi A; Massotti M
    Adv Biochem Psychopharmacol; 1974; 10():109-20. PubMed ID: 4546514
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of 6-hydroxydopamine treatments on active avoidance responding: evidence for involvement of brain dopamine.
    Cooper BR; Breese GR; Grant LD; Howard JL
    J Pharmacol Exp Ther; 1973 May; 185(2):358-70. PubMed ID: 4703827
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on the participation of the dopaminergic system in the central effects of chronically administered antidepressant drugs.
    Kozyrska C; Zebrowska-Lupina I
    Pol J Pharmacol Pharm; 1983; 35(2):115-26. PubMed ID: 6684769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of dopamine neural systems to the behavioral alterations produced by 6-hydroxydopamine administration into brain.
    Cooper BR; Breese GR
    Adv Biochem Psychopharmacol; 1974; 12(0):353-68. PubMed ID: 4609223
    [No Abstract]   [Full Text] [Related]  

  • 13. Interactions between agents stimulating and inhibiting the central dopamine receptors and octopamine.
    Jagiełło-Wójtowicz
    Acta Physiol Pol; 1980; 31(2):153-8. PubMed ID: 6771963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central effects of prostaglandins F2alpha and E1.
    Herman ZS; Kmieciak-Kolada K; Wolny HL; Slomińska-Zurek J; Bonczek A
    Pol J Pharmacol Pharm; 1976; 28(5):411-21. PubMed ID: 1012972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central action of glucagon.
    Morawska D; Sieklucka-Dziuba M; Kleinrok Z
    Pol J Pharmacol; 1998; 50(2):125-33. PubMed ID: 9798264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The central action of intraventricularly (ivc) administered propranolol and phentolamine in rat.
    Kleinrok Z; Ksiazek A; Przesmycki K; Kolasa K
    Pol J Pharmacol Pharm; 1975; 27(4):405-12. PubMed ID: 1166021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine?
    Zieve L; Olsen RL
    Gut; 1977 Sep; 18(9):688-91. PubMed ID: 342358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of intracerebroventricularly administered octopamine, phenylethylamine and epinephrine on the central serotonergic system of the rat.
    Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1982; 34(4):193-200. PubMed ID: 6820690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of neonatal and adult hyperthyroidism on behavior and biosynthetic capacity for norepinephrine, dopamine and 5-hydroxytryptamine in rat brain.
    Rastogi RB; Singhal RL
    J Pharmacol Exp Ther; 1976 Sep; 198(3):609-18. PubMed ID: 978462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased fixed-ratio performance and differential d- and l-amphetamine action following norepinephrine depletion by intraventricular 6-hydroxydopamine.
    Peterson DW; Sparber SB
    J Pharmacol Exp Ther; 1974 Dec; 191(3):349-57. PubMed ID: 4427285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.